Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Lantern Pharma Inc. (LTRN : NSDQ)
 
 • Company Description   
Lantern Pharma Inc.is a biotechnology company. It develops medicines for multi-drug treatment resistance cancers focusing on prostate and ovarian cancers. The company's drug candidate consist LP-100, LP-300 and LP-184 which are in clinical stage. Lantern Pharma Inc.is based in Dallas, Texas.

Number of Employees: 24

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.54 Daily Weekly Monthly
20 Day Moving Average: 234,452 shares
Shares Outstanding: 10.78 (millions)
Market Capitalization: $38.18 (millions)
Beta: 1.54
52 Week High: $6.12
52 Week Low: $2.55
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 5.04% 1.89%
12 Week 0.57% -12.82%
Year To Date 10.97% 4.84%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1920 MCKINNEY AVENUE 7TH FLOOR
-
DALLAS,TX 75201
USA
ph: 972-277-1136
fax: -
ir@lanternpharma.com http://www.lanternpharma.com
 
 • General Corporate Information   
Officers
Panna Sharma - Chief Executive Officer and President
Donald J. Keyser - Chairman
David R. Margrave - Chief Financial Officer
Maria Maccecchini - Director
Vijay Chandru - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 51654W101
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/14/25
Share - Related Items
Shares Outstanding: 10.78
Most Recent Split Date: (:1)
Beta: 1.54
Market Capitalization: $38.18 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.44 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.81 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/14/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.28
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 17.65%
vs. Previous Quarter: 22.22%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -83.26
12/31/24 - -72.61
ROA
06/30/25 - -
03/31/25 - -70.65
12/31/24 - -63.37
Current Ratio
06/30/25 - -
03/31/25 - 4.86
12/31/24 - 5.83
Quick Ratio
06/30/25 - -
03/31/25 - 4.86
12/31/24 - 5.83
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - 1.56
12/31/24 - 1.96
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©